NKGen Biotech

NKGen Biotech Financing Cash Flow

The Net Financing Cash Flow of NKGen Biotech (NKGN) as of Nov 22, 2026 is 20.85 M USD. In the previous year, Net Financing Cash Flow was 22.16 M USD — a change of -5.88% (lower).

Financing Cash Flow

20.85 MUSD

YoY

-5.88%

Last updated:

Net Financing Cash Flow of NKGen Biotech is 2025 20.85 M USD. Net Financing Cash Flow of NKGen Biotech was 2024 22.16 M USD. It decreases by -5.88% lower compared to the previous year.

The NKGen Biotech Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2021
20.16 M USD
Jan 1, 2022
22.49 M USD
Jan 1, 2023
22.16 M USD
Jan 1, 2025
20.85 M USD
The NKGen Biotech Financing Cash Flow history
YEARFinancing Cash FlowYoY
20.85 MUSD-5.88%
22.16 MUSD-1.47%
22.49 MUSD+11.54%
20.16 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Net Financing Cash Flow of NKGen Biotech is 20.85 M USD in 2025.

Net Financing Cash Flow of NKGen Biotech changed from 22.16 M USD to 20.85 M USD, representing a -5.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's NKGen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NKGen Biotech

All Key Metrics — NKGen Biotech